Biotech Startups

Dispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.

1 investor

Ditto Bio uses AI to identify protein candidates from parasites and pathogens for treating autoimmune diseases. The company mines natural compounds from viruses, ticks, and worms whose immune-modulating properties have evolved over millions of years.

1 investor

DLeader develops an AI-powered platform for automated drug discovery that accelerates the research and development process for pharmaceutical researchers. The platform uses generative AI tools to support and optimize the drug discovery workflow.

1 investor

DNA Gensee runs a DNA analysis laboratory and R&D consultancy that identifies plant and algae species in raw materials, ingredients, and finished products using molecular biology techniques. It serves industrial manufacturers using plants or algae, verifying botanical and geographic authenticity, traceability, safety, and quality of natural extracts.

1 investor

DNAiTECH develops molecular diagnostic tests for point-of-care applications, including its PLACID platform combining paper-based LAMP-CRISPR technology, serving both medical and agricultural diagnostic markets. The company focuses on accessible diagnostics for conditions including ME/CFS, Long COVID, and veterinary/agritech applications.

1 investor

DNAsimple connects individuals with medical research studies, matching them to researchers' requests and paying rewards for contributing biological samples (blood, urine) and completing health surveys. It lets participants share their medical records and de-identified health data, and complete studies at home or with a visiting clinician.

1 investor

DNAstack builds Omics AI, a software suite that lets data custodians connect, protect, and share omics and health data across federated networks while enabling researchers to discover, access, and analyze it with AI tools. It serves genomics and health research organizations, including national and international research networks in areas such as pandemic surveillance, neuroscience, rare disease, and oncology, using open GA4GH standards.

1 investor

Dolinnov is a pharmaceutical company developing next-generation painkillers based on a Precision Pump Modulator that targets the ion pump driving neuronal hyperexcitability rather than blocking ion channels. It focuses on treatments for extreme chronic pain and other serious diseases with significant unmet medical needs.

1 investor

Dutscher provides after-sales service (SAV) and post-delivery support (SAL) for laboratory equipment and consumables, handling warranty claims, non-warranty repairs, maintenance, product returns, and transport damage resolution.

1 investor

Domus develops molecular testing platforms that perform nucleic acid detection in a single-step reaction across three deployment models: at-home rapid tests, clinic-based instruments, and central laboratory assays. The company serves clinical diagnostics and at-home testing markets with technology optimized for sensitivity, simplicity, and low cost.

1 investor

Publicly listed pharmaceutical company

1 investor

DP Bio Innovations is developing an implantable, bioresorbable medical device that regenerates a damaged esophagus inside the body, intended to treat patients with severe GERD/advanced Barrett's Esophagus, esophageal cancer, and pediatric esophageal defects. The device aims to avoid surgical reconstruction such as gastric pull-up and reduce treatment costs compared to the standard of care.

1 investor

Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies. The company, a spin-out from Aarhus University and Max-Planck Society, builds proprietary platform technology to treat diseases with significant unmet medical need.

1 investor

DR.C Medicine (DRC Medicine Ltd.) is a Japanese company specializing in allergy and infectious-disease countermeasures, developing and selling pharmaceuticals, medical devices, quasi-drugs, healthcare and cosmetic products. It develops materials based on its Hydro Silver Titanium technology, used in products such as masks, towels, socks and air purifiers.

1 investor

Muu develops animal-free proteins using precision fermentation, cultivating proprietary microbial hosts to bio-manufacture protein that is then purified into a high-purity protein powder. Its ingredients target the nutrition and fitness supplement market with a lower land, water, and greenhouse-gas footprint than animal-derived protein.

1 investor

Droia Ventures is a specialist venture capital firm investing globally in early-stage drug development companies focused on therapeutics for oncology and genetic disease. It backs and co-creates biotech companies, supporting them from formation through clinical proof of concept via its in-house team and its scientific arm, Droia Labs.

1 investor

DropCode uses proprietary droplet microfluidics with a dual barcode technology to run millions of protein-screening experiments per hour, combined with AI analysis to discover novel, optimized proteins for customers. The company applies high-throughput biological data-mining to characterize protein function and design new-to-nature proteins.

1 investor

DropLab is a multidisciplinary engineering firm specializing in microfluidics technology, serving customers with challenges in nanotechnology, biomedicine, and materials engineering.

1 investor

Dropprint Genomics develops software for analyzing individual cell activity in genomic data, serving researchers in immunology and drug discovery. The company reduces the cost and computational complexity of single-cell sequencing and maintains a database of over 1 million immune cells to support target identification using machine learning models.

1 investor

DrugBank develops a comprehensive drug knowledge base and API that provides curated, machine-learning ready data on drugs and drug products to pharmaceutical companies, researchers, and healthcare organizations. The company makes scientific findings and biomedical information accessible to improve medical outcomes and drug discovery.

1 investor

The Dry Lab builds tools that help researchers and organizations convert raw data into discoveries through connected systems and intelligent automation.

1 investor

Dryland Genetics is a plant breeding company developing productive, resilient crop varieties, with expertise in the North American corn market and broader crop genetics. It applies crop biology, genetics, and bioinformatics to build commercial seed portfolios.

1 investor

DST develops allergy and food intolerance diagnostic products for medical laboratories and healthcare professionals, including laboratory tests and point-of-care testing systems. The company focuses on tailored diagnostic solutions for different geographic regions.

1 investor

Duo Oncology is a clinical-stage company developing tumor-activated prodrug combinations intended to replace toxic multi-agent chemotherapy with single medicines that concentrate activity in tumors. Its lead candidate, DUO-207, combines gemcitabine and paclitaxel into a single-infusion prodrug positioned as a chemotherapy backbone for use with KRAS inhibitors in solid tumors such as pancreatic, lung, and breast cancer.

1 investor